HIV Vaccines

产品说明： 此应用程序请求支持由Gunilla B组织的名为HIV疫苗的Keystone研讨会会议。卡尔森赫德斯塔姆，安德鲁麦克迈克尔和克里斯托弗J米勒，这将是在基斯通，科罗拉多从2012年3月21日至26日举行。2012年关于艾滋病毒疫苗的Keystone研讨会会议将重点讨论免疫学和HIV-1病毒学的基本方面，以强调该领域面临的挑战问题。流行的HIV-1变异体的遗传多样性对预防性疫苗需要引起的反应的质量提出了极高的要求。最有可能的是，保守的病毒决定因素需要被靶向，并且反应必须随着时间的推移而持续。为了促进围绕这些主题进行广泛和公开的讨论，研讨会将召集来自HIV-1疫苗领域的专家调查人员以及一些基础免疫学家。与疫苗开发直接相关的自然HIV-1感染方面，如病毒传播和病毒逃避免疫反应，将在与病毒免疫和宿主基因影响平行会议的联合会议上讨论。还将邀请发言者根据提交的摘要在讲习班和口头会议上发言。 公共卫生相关性： 艾滋病毒-1/艾滋病是最主要的传染病，在全世界造成死亡和发病。显然，遏制这一疾病未来影响的最有效办法是在全世界开发和提供安全、有效和负担得起的疫苗，以预防或减少病毒的传播。在过去几年中，Keystone Symposia HIV疫苗系列会议在汇集从事HIV疫苗基础和转化方面工作的科学家社区方面发挥了重要作用。2012年的会议-与病毒免疫和宿主基因影响会议一起举行-旨在促进基础免疫学家和艾滋病毒学家之间的互动。我们预计，这两个领域之间的相互作用的增加将使艾滋病毒疫苗界受益匪浅。

DESCRIPTION: This application requests support for a Keystone Symposia meeting entitled HIV Vaccines, organized by Gunilla B. Karlsson-Hedestam, Andrew McMichael and Christopher J. Miller, which will be held in Keystone, Colorado from March 21 - 26, 2012. The 2012 Keystone Symposia meeting on HIV Vaccines will focus on basic aspects of immunology and HIV-1 virology to highlight issues that challenge the field. The genetic diversity of circulating HIV-1 variants puts extreme demands on the quality of the response a prophylactic vaccine will need to elicit. Most likely, conserved viral determinants need to be targeted and the response must be sustained over time. To facilitate a broad and open discussion around these topics, the symposium will convene expert investigators from the HIV-1 vaccine field as well as a number of basic immunologists. Aspects of natural HIV-1 infection of direct relevance to the development of a vaccine, such as viral transmission and viral escape from immune responses, will be addressed in joint sessions with the parallel meeting on Viral Immunity and Host Gene Influence. Speakers will also be invited to present in the workshops and in the oral sessions based on submitted abstracts. PUBLIC HEALTH RELEVANCE: The HIV-1/AIDS pandemic is the foremost infectious disease, causing death and morbidity worldwide. Clearly the most effective approach to curbing the future impact of this disease is through the development and delivery worldwide of a safe, effective and affordable vaccine that prevents or reduces transmission of the virus. Over the past several years, the Keystone Symposia HIV Vaccines meeting series has played an important role in bringing together the community of scientists working on basic and translational aspects of HIV vaccines. The 2012 meeting - held in conjunction with a meeting on Viral Immunity and Host Gene Influence - aims to stimulate increased interactions between basic immunologists and HIV virologists. We anticipate increased interactions between these two fields will benefit the HIV vaccine community enormously.